We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Asuragen Launches Mirna Therapeutics to Develop and Commercialize microRNA Oncology Therapeutics
News

Asuragen Launches Mirna Therapeutics to Develop and Commercialize microRNA Oncology Therapeutics

Asuragen Launches Mirna Therapeutics to Develop and Commercialize microRNA Oncology Therapeutics
News

Asuragen Launches Mirna Therapeutics to Develop and Commercialize microRNA Oncology Therapeutics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Asuragen Launches Mirna Therapeutics to Develop and Commercialize microRNA Oncology Therapeutics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Asuragen, Inc. announced today the launch of Mirna Therapeutics, a new company focused on the development and commercialization of microRNA (miRNA) therapeutics.

miRNAs are naturally occurring small RNAs that regulate whole networks of genes in a coordinated manner and play key roles in a variety of biological processes. miRNA levels are substantially reduced in a wide variety of cancers and Mirna scientists have found that replacement of these down regulated miRNAs with synthetic miRNAs results in a positive therapeutic response in cell culture and animal models of cancer. In collaboration with Yale University, Mirna has pioneered the concept of “miRNA replacement therapy”.

“The discovery of miRNAs represents a paradigm changing event in biology and medicine of a magnitude that only occurs once every decade or two”, said Matt Winkler CEO/CSO of Asuragen. “They likely will become a major new class of drugs”

Asuragen is transferring its miRNA therapeutic intellectual property to Mirna Therapeutics and seeding the new company with $3M in capital. Asuragen was created in early 2006 in connection with the sale of Ambion to Applied Biosystems with the goal of developing both miRNA diagnostic and therapeutic products.

“Based upon Asuragen’s unique miRNA biomarker discovery platform, the miRNA therapeutic program has progressed to a point where it deserves the funding and development expertise to focus solely on therapeutics,” said Winkler. “Therapeutic development requires an entirely different skill set and funding strategy than diagnostics. Mirna Therapeutics will operate as an independent company with its own management team and Board of Directors.”

Advertisement